Proscia secures $50M for digital pathology
Proscia, a digital pathology company, closed a $50 million Series B funding round.
Investment firms Insight Partners and Triangle Peak joined venture capital firm AI Capital Partners as co-leads in the round. Other investors included Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures and Razor’s Edge.
Related:Top digital health funding: Intermountain backs Vori Health
Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic laboratories at providers or third party organizations. The company has developed a centralized software platform that scans images of pathology slides rather than physical samples.
The company said the funding will be used to help it scale to more customers and add more AI features to its platform. The round brings Proscia’s total raised to $130 million.
Inspiren raises $35M for senior living tech
Inspiren, a startup focused on senior living communities, closed a $35 million Series A funding round.
Investment firm Avenir led the round. Venture capital firms Primary Venture Partners, Story Ventures, Third Prime and Studio VC also participated.
The company sells workflow and staffing technology as well a fall detection tool to senior living facilities. Inspiren said it would use the funding to scale and hire additional staff.
The round brings the company’s total raised to $55 million.
Brainomix, University of Oxford spinoff, nabs $18M
Brainomix, an imaging company focused on stroke and lung fibrosis patients, closed an $18 million funding round.
London-based Parkwalk Advisors, Germany-based Boehringer Ingelheim Venture Fund and Australian pension fund Hostplus co-led the round. Investment bank LifeSci Capital participated in the round.
Brainomix sells an AI-enabled stroke imaging software to hospitals and health systems. The company has also developed AI algorithms to assess CT scans of patients with lung disease. Brainomix, which spun-out from the University of Oxford 2012, will use the funding to accelerate commercial expansion in the U.S.
The round brings its total raised to $57 million.
Click Therapeutics raises Series C round
Click Therapeutics, a digital therapeutics company, raised a Series C funding round.
The company did not disclose the amount.
Dassault Systèmes, a clinical trial technology, was the sole investor in the round.
Click Therapeutics said in a news release the funding would help the companies establish a deeper partnership for clinical trials. Click joined a serious of other digital therapeutics companies in acquiring the portions of shuttered Pear Therpeutics in 2023.
